John Theurer Cancer Center Investigators Presenting at ASCO

Published:
May 29, 2019

What you need to know

Researchers from John Theurer Cancer Center (JTCC) at Hackensack are presenting data from 23 studies at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO).

ASCO is being held in Chicago from May 31-June 4, 2019. Abstracts of the studies can be viewed at abstracts.asco.org.

Many of the studies being presented at ASCO report on novel treatments for patients with recurrent or persistent lymphoma or multiple myeloma, including innovative precision medicine approaches.

What is JTCC presenting

Data from the following studies by JTCC researchers will be presented at ASCO:

Lymphoma

  • A phase Ib/II study of oral nanatinostat and valganciclovir in subjects with Epstein-Barr virus-associated lymphomas (abstract 7551)
  • Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: Three-year update of the ECHELON-1 study (abstract 7532)
  • Cost-effectiveness of brentuximab vedotin with chemotherapy in frontline treatment of CD30-expressing peripheral T-cell lymphoma (abstract E19060)
  • Phase 1 study of CA-4948, a novel inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) in patients with recurrent/refractory non-Hodgkin lymphoma (abstract E19055)
  • Response to A+CHP by CD30 expression in the ECHELON-2 trial (abstract 7538)
  • Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study (abstract 7506)

Multiple Myeloma

  • A health-related quality-of-life analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment (abstract 8025)
  • Carfilzomib in relapsed and refractory multiple myeloma: Frailty subgroup analysis from phase III ASPIRE and ENDEAVOR (abstract 8028)
  • Once-weekly (70 mg/m2) versus twice-weekly (56 mg/m2) dosing of carfilzomib for patients with relapsed and/or refractory multiple myeloma (abstract E19505)
  • Prospective study to measure the impact of MMprofiler on treatment intention in newly diagnosed multiple myeloma patients (PROMMIS) (abstract 8030)
  • The myeloma-developing regimens using genomics (MyDRUG) master protocol (abstract TPS8057)
  • Treatment patterns and outcomes among t(11;14) myeloma patients in a real-world setting (abstract E19531)

Lung Cancer

  • Antitumor activity and safety of MK-1308 (anti-CTLA-4) plus pembrolizumab in patients with non-small cell lung cancer: Updated interim results from a phase I study (abstract 2558)
  • Biomarker-directed precision oncology of pembrolizumab-based combination therapy for non-small cell lung cancer: Phase II KEYNOTE-495/KeyImPaCT study (abstract TPS9117)
  • Real-world characterization of advanced/metastatic non-small cell lung cancer patients with rapid disease progression (E20706)

Colorectal Cancer

  • Rates of genotyping for KRAS, NRAS, BRAF, microsatellite instability, and mismatch repair in metastatic colon cancer patients: Gaps and implications (abstract E15123)

Hepatobiliary Cancers

  • A phase I study of H3B-6527 in hepatocellular carcinoma or intrahepatic cholangiocarcinoma (ICC) patients (abstract 4095)

Ovarian Cancer

  • Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208) (abstract TPS5602)

Urothelial Cancer

  • Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer: HCRN GU14-182 (abstract 4504)

Solid Tumors

  • A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors (abstract 2523)
  • Prognostic value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with advanced solid tumors treated with PD-1 inhibitors (abstract E14132)

Other Cancer Care Topics

  • Accelerating advanced precision medicine through a harmonized data exchange platform and research consortium (PMEC) (abstract 6557)
  • It starts at the top: An analysis of female representation in academic medical oncology, radiation oncology, and surgical oncology program leadership positions (abstract 10520)